Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy
Immunovant Inc IMVT
$38.62
▼ -2.18%
($-0.86)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$39.31
Prev Close
$39.48
Day Range
$38.00 – $39.32
52W Range
$14.32 – $41.23
Market Cap
$7.97B
Beta
0.82
EPS (TTM)
$-2.77
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-05-14 |
| Shares Out. | 206,400,000 |
| Website | immunovant.com/ ↗ |
| Phone | 13026365400 |
| Employees | 315 |
| Net Income | -$147.9M |
| Free Cash Flow | -$407.3M |
| Total Assets | $957.0M |
| Total Liabilities | $104.4M |
| Equity | $852.6M |
About Immunovant Inc
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Immunovant Inc is a publicly traded company under the ticker symbol IMVT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
24 analysts (2026-07-01)